Skip to main content
SpringerLink
Log in

Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I

  • Reviews
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Preclinical efforts to detect and characterize potential cognition enhancers appear to have been dominated by a strategy of demonstrating a wide variety of apparently beneficial behavioral effects with little attention given to the specific psychological mechanisms underlying behavioral enhancement. In particular, the question of whether or not behavioral facilitation is based on relevant mnemonic mechanisms and is independent of the stimulus properties and/or the motivational and attentional components of a task is not often considered. As a result, an overwhelming number of compounds have failed to produce the clinical effects predicted for them on the basis of preclinical research. The available data suggest that a more successful approach requires deductive research strategies rather than the indiscriminate accumulation of apparently beneficial effects in a variety of behavioral tasks and animal models. The first step towards such an approach is a systematic and rigorous evaluation of the different aspects of validity for the models most frequently used in preclinical research. It is concluded that a combination of good construct validity and good face validity represents a necessary condition for screening tests with predictive validity, and that the most popular paradigms fail to fulfil these criteria. Future screening programs for cognition enhancers will probably be characterized by a depreciation of “fast and dirty tests” in favor of approaches focussing on the validity of the effects of potential cognition enhancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Bagne CA, Pomara N, Crook T, Gershon S (1986) Alzheimer's disease: strategies for treatment and research. In: Crook T, Bartus R, Ferris S, Gershon S (eds) Treatment development strategies for Alzheimer's disease. Mark Powley, Madison, pp 585–638

    Google Scholar 

  • Barnas C, Miller C, Gunther V, Fleischhacker W (1987) Treatment of alcohol organic mental disorder with piracetam. Progr Neuropsychopharmacol Biol Psychiatry 11:729–737

    Article  Google Scholar 

  • Barnes JM, Costall B, Coughlan J, Domeney AM, Gerrard PA, Kelly ME, Naylor RJ, Onaivi ES, Tomkins DM, Tyers MB (1990) The effects of ondansetron, a 5-HT3 receptor antagonist, on cognition in rodents and primates. Pharmacol Biochem Behav 35:955–962

    Google Scholar 

  • Barondes SH (1969) Cerebral protein synthesis inhibitors block long term memory. Int Rev Neurobiol 12:177–205

    Google Scholar 

  • Barraco RA, Stettner LJ (1976) Antibiotics and memory. Psychol Bull 2:242–302

    Google Scholar 

  • Bartus RT (1978) Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine. Pharmacol Biochem Behav 9:833–836

    Google Scholar 

  • Bartus RT (1988) The need for common perspectives in the development and use of animal models for age-related cognitive and neurodegenerative disorders. Neurobiol Aging 9:445–451

    PubMed  Google Scholar 

  • Bartus RT, Dean RL, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408–417

    Google Scholar 

  • Beatty WW, Butters N, Janowski DS (1986) Patterns of memory failure after scopolamine treatment: implications for cholinergic hypotheses of dementia. Behav Neural Biol 45:196–211

    Google Scholar 

  • Becker RE, Giacobini E (1988) Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type: clinical, pharmacological, and therapeutic aspects. Drug Dev Res 12:163–195

    Article  Google Scholar 

  • Beninger RJ (1989) Methods for determining the effects of drugs on learning. In: Boulton AA, Baker GB, Greenshaw AJ (eds) Neuromethods. Psychopharmacology, vol 13. Humana Press, Clifton, pp 623–685

    Google Scholar 

  • Biegon A, Greenberger V, Segal M (1986) Quantitative histochemistry of brain acetylcholinesterase and learning rate in the aged rat. Neurobiol Aging 7:215–217

    Article  PubMed  Google Scholar 

  • Bruno G, Mohr E, Gillespie M, Fedio P, Chase TN (1986) Muscarinic agonist therapy of Alzheimer's disease: a clinical trial of RS-86. Arch Neurol 43:659–661

    PubMed  Google Scholar 

  • Byrne J, Arie T (1989) Tetrahydroaminoacridine (THA) in Alzheimer's disease. BMJ 298:845–846

    PubMed  Google Scholar 

  • Caine ED (1980) Cholinomimetic treatment fails to improve memory disorders. N Engl J Med 303:585–586

    Google Scholar 

  • Caltagirone C, Gainotti C, Masullo O (1982) Oral administration of chronic physostigmine does not improve cognitive or mnesic performances in Alzheimer's presenile dementia. Int J Neurosci 16:247–249

    PubMed  Google Scholar 

  • Chatelier G, Lacomblez L, et al (1990) Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer's type: a multicentre trial. BMJ 300:495–499

    PubMed  Google Scholar 

  • Chouinard G, Annable L, Ross-Chouinard A, Olivier M, Fontaine F (1983) Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment. Psychopharmacology 81:100–106

    Google Scholar 

  • Christie JE, Shering A, Ferguson J, Glem AIM (1981) Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry 138:46–50

    PubMed  Google Scholar 

  • Claus JJ, Ludwig C, Mohr E, Giuffra M, Blin J, Chase TN (1991) Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam. Neurology 41:570–574

    PubMed  Google Scholar 

  • Collerton D (1986) Cholinergic function and intellectual decline in Alzheimer's disease. Neuroscience 19:1–28

    Article  PubMed  Google Scholar 

  • Cumin R, Bandle EF, Gamzu E, Haefely, WE (1982) Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. Psychopharmacology 78:104–111

    Google Scholar 

  • Davidson M, Zemishlany Z, Mohs RC, Horvath TB, Powchik P, Blass JP, Davis KL (1988) 4-Aminopyridine in the treatment of Alzheimer's disease. Biol Psychiatry 23:485–490

    Article  PubMed  Google Scholar 

  • Davis B, Andrewes D, Stargatt R, Ames D, Tuckwell V, Davis S (1990) Tetrahydroaminoacridine in Alzheimer's disease. Int J Geriat Psychiatry 5:317–321

    Article  Google Scholar 

  • Davis JW, Thomas RK, Adams HE (1971) Interactions of scopolamine and physostigmine with ECS and one trial learning. Physiol Behav 6:219–222

    Google Scholar 

  • Davis KL, Hollander E, Davidson M, Davis BM, Mohs RC, Horvath TB (1987) Induction of depression with oxotremorine in patients with Alzheimer's disease. Am J Psychiatry 144:468–471

    PubMed  Google Scholar 

  • Deacon RMJ, Budhram P, Dawson D, Galliani G, Guy AP, Gardner CR (1990) Investigation of potential cognition enhancing properties of RU 33965, a benzodiazepine receptor partial inverse agonist. Psychopharmacology 101 [suppl]:45

    Google Scholar 

  • Dean RL, Bartus RT (1988) Behavioral models of aging in nonhuman primates. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of psychopharmacology. Psychopharmacology of the aging nervous system, vol 20. Plenum Press, New York, pp 325–392

    Google Scholar 

  • Dekker JAM, Connor DJ, Thal LJ (1991) The role of cholinergic projections from the nucleus basalis in memory. Neurosci Biobehav Rev 15:299–317

    Google Scholar 

  • DeNoble VJ, Repetti SJ, Gelpke, LW, Wood LM, Keim KL (1986) Vincopetine: nootropic effects on scopolamine-induced and hypoxia-induced retrieval deficits of a step-through passive avoidance response in rats. Pharmacol Biochem Behav 24:1123–1128

    Article  PubMed  Google Scholar 

  • Devanand DP, Sackeim HA, Brown RP, Mayeux R (1989) A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease. Arch Neurol 46:854–857

    PubMed  Google Scholar 

  • Dokla CPJ, Thal LJ (1988) Effect of cholinesterase inhibitors on Morris water task behavior following lesions of the nucleus basalis magnocellularis. Behav Neurosci 102:861–871

    Article  PubMed  Google Scholar 

  • Dokla CPJ, Parker SC, Thal LJ (1989) Tetrahydroaminoacridine facilitates passive avoidance learning in rats with nucleus basalis magnocellularis lesions. Neuropharmacology 11:1279–1282

    Article  Google Scholar 

  • Duka T, Stephens DN, Krause W, Dorow R (1987) Human studies on the benzodiazepine receptor antagonist β-carboline ZK 93 426: preliminary observations on psychotropic activity. Psychopharmacology 93:421–427

    Google Scholar 

  • Duka T, Edelmann V, Schütt B, Dorow R (1988) β-Carboniles as tools in memory research: human data with the β-carboline ZK 93 426. In: Hindmarch I, Ott H (eds) Benzodiazepine receptor ligands, memory and information processing. Springer, Berlin Heidelberg New York, pp 246–260

    Google Scholar 

  • Duncan CP (1949) The retroactive effect of electroshock on learning. J Comp Physiol Psychol 42:32–44

    Google Scholar 

  • Essman WB (1971) Drug effects and learning and memory processes. Adv Pharmacol Chemother 9:241–330

    PubMed  Google Scholar 

  • Fisher A, Brandeis R, Pittel Z, Karton I, Sapir M, Dachir S, Levy A, Heldman E (1989) (+/-)-cis-2-methyl-spiro (1,3-oxathiolane-5,3') guinuclidine (AF102B): a new M1 agonist attenuates cognitive dysfunctions in AF64A treated rats. Neurosci Lett 102:325–331

    Article  PubMed  Google Scholar 

  • Fitten LJ, Perryman KM, Gross PL, Fine H, Cummins J, Marshall C (1990) Treatment of Alzheimer's disease with short- and long-term oral THA and lecithin: a double-blind study. Am J Psychiatry 147:239–242

    PubMed  Google Scholar 

  • Flicker C, Serby M, Ferris SH (1990) Scopolamine effects on memory, language, visuospatial praxis and psychomotor speed. Psychopharmacology 100:243–250

    Google Scholar 

  • Flood JF, Cherkin A (1986) Scopolamine effects on memory retention in mice: A model for dementia? Behav Neural Biol 45:169–184

    Article  PubMed  Google Scholar 

  • Flood JF, Vidal D, Bennett EL, Orme AE, Vasquez S, Jarvik ME (1978) Memory facilitation and anti-amnesic effects of corticosteroids. Pharmacol Biochem Behav 8:81–87

    Google Scholar 

  • Forsyth DR, Surmon DJ, Morgan RA, Wilcock GK (1989) Clinical experience with side effects of tacrine hydrochloride in Alzheimer's disease: a pilot study. Age Ageing 18:223–229

    PubMed  Google Scholar 

  • Foster NL, Aldrich MS, Bluemlein L, White RF, Berent S (1989) Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep. Neurology 39:257–261

    PubMed  Google Scholar 

  • Freedman LS, Judge ME, Quartermain D (1982) Effect of cycloheximide, a protein synthesis inhibitor, on mouse brain catecholamine biochemistry. Pharmacol Biochem Behav 17:187–191

    Google Scholar 

  • Gash DM, Thomas GH (1983) What is the importance of vasopressin in memory processes? TINS 6:197–198

    Google Scholar 

  • Gauthier S, Bouchard R, Lamontagne A, Bailey P, Bergman H, Ratner J, Tesfaye Y, Saint-Martin M, Bacher Y, Carrier L, Charbonneau R, Clarfield AM, Collier B, Dastoor D, Gauthier L, Germain M, Kissel C, Krieger M, Kushnir S, Masson H, Morin J, Nair V, Neirink L, Suissa S (1990) Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate stage Alzheimer's disease. N Engl J Med 322:1272–1276

    PubMed  Google Scholar 

  • Gauthier S, Bouchard R, Bacher Y, Bailey P, Bergman H, Carrier L, Carbaonneau R, Clarfield M, Bollier B, Dastorr D, Gauthier L, Germain M, Kissel M, Krieger M, Kushnir S, Lamontagne A, Morin J, Nair NPV, Neirinck L, Ratner J, St-Martin M, Suissa S, Tesfaye Y (1989) Progress report on the Canadian multicentre trial of tetrahydroaminoacridine with lecithin in Alzheimer's disease. Can J Neurol Sci 16:543–546

    PubMed  Google Scholar 

  • Geula C, Mesulam MM (1989) Cortical cholinergic fibers in aging and Alzheimer's disease: a morphometric study. Neuroscience 33:469–481

    Article  PubMed  Google Scholar 

  • Growdon JH, Corkin S, Huff FJ, Rosen TJ (1986) Piracetam combined with lecithin in the treatment of Alzheimer's disease. Neurobiol Aging 7:269–276

    Article  PubMed  Google Scholar 

  • Hagan JJ, Morris RGM (1988) The cholinergic hypothesis of memory: a review of animal experiments. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of psychopharmacology. Psychopharmacology of the aging nervous system, vol 20. Plenum Press, New York, pp 237–232

    Google Scholar 

  • Hagan JJ, Jansen JHM, Broekkamp CLE (1989) Hemicholinium-3 impairs spatial learning and the deficit is reversed by cholinomimetics. Psychopharmacology 98:347–356

    Google Scholar 

  • Hagan JJ, Jansen JHM, Nefkens FEW, de Boer T (1990) Therapeutic effect of THA on hemicholinium-3 induced learning impairment is dependent of serotonergic and noradrenergic systems. Psychopharmacology 101:376–383

    Google Scholar 

  • Handelmann GE, Nevins ME, Mueller LL, Arnolde, SM, Cordi AA (1989) Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnesic rodents. Pharmacol Biochem Behav 34:823–828

    Google Scholar 

  • Harbaugh RE, Reeder TM, Senter HJ, Knopman DS, Raskin DS, Pirozzolo F, Chang-Chui H, Shetter AG, Bakay RAE et al. (1989) Intracerebroventricular bethanecol chloride infusion in Alzheimer's disease. J Neurosurg 71:481–486

    PubMed  Google Scholar 

  • Haroutunian V, Kanof PD, Davis K (1985) Pharmacological alleviation of cholinergic lesion induced memory deficits in rats. Life Sci 37:945–952

    Article  PubMed  Google Scholar 

  • Haroutunian V, Kanof PD, Tsuboyama GK, Campbell GA, Davis KL (1986) Animal models of Alzheimer's disease: behavior, pharmacology, transplants. Can J Neurol Sci 13:385–393

    PubMed  Google Scholar 

  • Haroutunian V, Kanof PD, Tsuboyama GK, Campbell GA, Davis KL (1990a) Restoration of cholinomimetic activity by clonidine in cholinergic plus adrenergic lesioned rats. Brain Res 507:261–266

    Article  PubMed  Google Scholar 

  • Haroutunian V, Mantin R, Kanof PD (1990b) Frontal cortex as the site of action of physostigmine in nBM lesioned rats. Physiol Behav 47:203–206

    Google Scholar 

  • Heise GA (1984) Behavioral methods for measuring effects of drugs on learning and memory in animals. Med Res Rev 4:534–558

    Google Scholar 

  • Henderson VW, Roberts E, Wimer C, Bardolph EL, Chui HC, Damasio AR, Eslinger PJ, Goldstein MF, Schneider LS, Teng EL, Tune LE, Weiner LP, Whitehouse PJ (1989) Multicenter trial of naloxone in Alzheimer's disease. Ann Neurol 25:404–406

    Article  PubMed  Google Scholar 

  • Hinde RA (1976) The use of differences and similarities in comparative psychopathology. In: Serban G, Kling A (eds) Animal models in human psychobiology. Plenum Press, New York, pp 187–202

    Google Scholar 

  • Hock FJ, McGaugh JL (1985) Enhancing effects of Hoe 175 on memory in mice. Psychopharmacology 86:114–117

    Google Scholar 

  • Hock FJ, Gerhards HJ, Wiemer G, Stechl J, Rüger W, Urbach H (1989) Effects of the novel compound, Hoe 065, upon impaired learning and memory in rodents. Eur J Pharmacol 171:79–85

    Article  PubMed  Google Scholar 

  • Hodges H, Ribeiro AM, Gray JA, Marchbanks RM (1990) Low dose tetrahydroaminoacridine (THA) improves cognitive function but does not affect brain acetylcholine in rats. Pharmacol Biochem Behav 36:291–298

    Google Scholar 

  • Hoffmeister F, Benz U, Heise A, Krause HP, Neuser V (1982) Behavioral effects of nimodipine in animals. Drug Res 32:347–360

    Google Scholar 

  • Hollander E, Davidson M, Mohs RC, Horvath TB, Davis BM, Zemishlany Z, Davis KL (1987) RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects. Biol Psychiatry 22:1067–1078

    Article  PubMed  Google Scholar 

  • Höhmann CF, Antuono P, Coyle JT (1988) Basal forebrain cholinergic neurons and Alzheimer's disease. In: Iversen LI, Snyder SH, Iversen SD (eds) Handbook of psychopharmacology. Plenum Press, New York, pp 69–106

    Google Scholar 

  • Huff FJ, Mickel SF, Corkin S, Growdon JH (1988) Cognitive functions affected by scopolamine in Alzheimer's disease and normal aging. Drug Dev Res 12:271–278

    Article  Google Scholar 

  • Izquierdo I (1989) Different forms of post-training memory processing. Behav Neural Biol 51:171–202

    Google Scholar 

  • Janssen PAJ (1964) Screening tests and prediction from animals to man. In: Steinberg H (ed) Animal behavior and drug action. Little, Brown, Boston, pp 264–268

    Google Scholar 

  • Jensen LH, Stephens DN, Sarter M, Petersen EN (1987) Bidirectional effects of β-carbolines and benzodiazepines on memory processes. Brain Res Bull 19:359–364

    Article  PubMed  Google Scholar 

  • Jones DNC, Carey GJ, Costall B, Domeney AM, Gerrard PA, Naylor RJ, Tyers MB (1990) Arecoline and ondansetron reverse scopolamine-induced deficits in an object discrimination task in the marmoset. Psychopharmacology 101 [suppl]:99

    Google Scholar 

  • Kameyama T, Nabeshima T, Noda Y (1986) Cholinergic modulation of memory for step down type passive avoidance task in mice. Res Communic Psychol Psychiatr Behav 2:193–206

    Google Scholar 

  • Kawajiri S, Sakurai T, Ojima H, Hatanaka S, Yamasaki T, Kojima H, Akashi A (1988) Effect of DM-9384, a new pyrrolidone derivative, on learning behavior and cerebral choline acetyltransferase activity in rats. Psychopharmacology 96 [suppl]:306

    Google Scholar 

  • Kelly PH, Enz A, Amstutz R (1990) Effects of cholinergic agents in a new two-trail swim test of exploration and memory formation. Psychopharmacology 102 [suppl]:104

    Article  Google Scholar 

  • Kolb B, Whishaw IQ (1990) Fundamentals of human neuropsychology. W.H. Freeman, New York

    Google Scholar 

  • Kopelman MD, Corn TH (1988) Cholinergic “blockade” as a model for cholinergic depletion. A comparison of the memory deficits with those of Alzheimer-type dementia and the alcoholic Korsakoff syndrome. Brain 111:1079–1110

    PubMed  Google Scholar 

  • Kwo-On-Yuen PF, Mandel R, Chen AD, Thal LJ (1990) Tetrahydroaminoacridine improves the spatial deficit produced by nucleus basalis lesions in rats. Expl Neurol 108:221–228

    Article  Google Scholar 

  • Lal H, Kumar B, Forster MJ (1988) Enhancement of learning and memory in mice by a benzodiazepine receptor antagonist. FASEB J 2:2707–2711

    PubMed  Google Scholar 

  • Levin ED (1988) Scopolamine interactions with D1 and D2 antagonists on radial-arm maze performance in rats. Behav Neural Biol 50:240–245

    Article  PubMed  Google Scholar 

  • Maho C, Dutrieux G, Ammassari-Teule M (1988) Parallel modifications of spatial memory performance, exploration patterns and hippocampal theta rhythms in fornix damaged rats: reversal by oxotremorine. Behav Neurosci 102:610–604

    Google Scholar 

  • Mandel RJ, Thal LJ (1988) Physostigmine improves water maze performance following nucleus basalis magnocellularis lesions in rats. Psychopharmacology 96:421–425

    Google Scholar 

  • Markstein R (1989) Pharmacological approaches in the treatment of senile dementia. Eur Neurol 29:33–41

    Google Scholar 

  • Martinez JL, Jensen RA, McGaugh JL (1981) Attenuation of experimentally-induced amnesia. Prog Neurobiol 16:155–186

    Article  PubMed  Google Scholar 

  • Mastropaolo J, Nadi NS, Ostrowski NL, Crawley JN (1988) Galanin antagonizes acetylcholine on a memory task in basal forebrain lesioned rats. Proc Natl Acad Sci USA 85:9841–9845

    PubMed  Google Scholar 

  • McGaugh JL (1989a) Dissociating learning and performance: drug and hormone enhancement of memory storage. Brain Res Bull 23:329–345

    Article  Google Scholar 

  • McGaugh JL (1989b) Involvement of hormonal and neuromodulatory systems in the regulation of memory storage. Annu Rev Neurosci 12:255–287

    Article  PubMed  Google Scholar 

  • McGaugh JL, Gold PE (1976) Modulation of memory by electrical stimulation of the brain. In: Rosenzweig MR, Bennett EL (eds) Neural mechanisms of learning and memory. MIT Press, Cambridge, pp 549–560

    Google Scholar 

  • McGurk SR, Levin ED, Butcher LL (1988) Cholinergic-dopaminergic interactions in radial-arm maze performance. Behav Neural Biol 49:234–239

    Google Scholar 

  • McKinney WT, Bunney WE (1969) Animal model of depression: review of evidence and implications for research. Arch Gen Psychiatry 21:240–248

    PubMed  Google Scholar 

  • Miyamoto M, Narumi S, Nagaoka A, Coyle JT (1989) Effects of continuous infusion of cholinergic drugs on memory impairment in in rats with basal forebrain lesions. J Pharmacol Exp Ther 248:825–835

    PubMed  Google Scholar 

  • Mohr E, Schlegel J, Fabbrini G, Williams J, Mouradian MM, Mann UM, Clauss JJ, Fedio P, Chase TN (1989) Clonidine treatment of Alzheimer's disease. Arch Neurol 46:376–378

    PubMed  Google Scholar 

  • Molchan SE, Mellow AM, Lawlor BA, Weingartner HJ, Cohen RM, Cohen MR, Sunderland T (1990) TRH attenuates scopolamine-induced memory impairment in humans. Psychopharmacology 100:84–89

    Google Scholar 

  • Molloy DW, Cape RDT (1989) Acute effects of oral pyridostigmine on memory and cognitive function in SDAT. Neurobiol Aging 10:199–204

    Article  PubMed  Google Scholar 

  • Moos WH, Davis RE, Schwartz RD, Gamzu EK (1988) Cognition activators. Med Res Rev 8:353–391

    PubMed  Google Scholar 

  • Mouradian MM, Mohr E, Williams JA, Chase TN (1988) No response to high dose muscarinic agonist therapy in Alzheimer's disease. Neurology 38:606–608

    PubMed  Google Scholar 

  • Murray CL, Fibiger HC (1985) Learning and memory deficits after lesions of the nucleus basalis magnocellularis: reversal by physostigmine. Neuroscience 14:1025–1032

    Article  PubMed  Google Scholar 

  • Murray CL, Fibiger HC (1986) Pilocarpine and physostigmine attenuate spatial memory impairments produced by lesions of the nucleus basalis magnocellularis. Behav Neurosci 100:23–32

    Article  PubMed  Google Scholar 

  • Nabeshima T, Yoshida S, Kameyama T (1988a) Effects of the novel compound NIK-247 on impairment of passive avoidance response in mice. Eur J Pharmacol 154:263–269

    Article  PubMed  Google Scholar 

  • Nabeshima T, Noda Y, Kameyama T (1988b) GABAergic modulation of memory with regard to passive avoidance and conditioned suppression tasks in mice. Psychopharmacology 94:69–73

    Google Scholar 

  • Nabeshima T, Noda Y, Tohyama K, Ithoh J, Kameyama T (1990a) Effects of DM-9384 in a model of amnesia based on animals with GABAergic neuronal dysfunctions. Eur J Pharmacol 178:143–149

    Article  PubMed  Google Scholar 

  • Nabeshima T, Tohyama K, Ichihara K, Kameyama T (1990c) Attenuation of benzodiazepine-induced passive avoidance deficit by post-training administration of muscimol: interaction with the cholinergic neuronal system. Eur J Pharmacol 182:555–560

    Article  PubMed  Google Scholar 

  • Nabeshima T, Tohyama K, Kameyama T (1990b) Effects of DM-9384, a pyrrolidone derivative, on alcohol- and chlordiazepoxide-induced amnesia in mice. Pharmacol Biochem Behav 36:233–236

    Google Scholar 

  • Nabeshima T, Tohyama K, Murase K, Ishihara S, Kameyama T, Yamsaki T, Hatanaka S, Kojima H, Sakurai T, Takasu Y, Shiotani T (1991) Effects of DM-9384, a cyclic derivative of GABA, on amnesia and decreases in GABAA and muscarinic rerceptors induced by cycloheximide. J Pharmacol Exp Ther 257:271–275

    PubMed  Google Scholar 

  • Nakahara N, Iga Y, Saito Y, Mizobe F, Kawanishi G (1989) Beneficial effects of FKS-508 (AF102B), a selective M1 agonist, on impaired working memory in AF64A treated rats. Jpn J Pharmacol 51:539–547

    PubMed  Google Scholar 

  • Nakahara N, Fujise N, Kawanishi G, Mizobe F (1990) Central muscarinic activities of an M1-selective agonist: preferential effect on reversal of amnesia. Brain Res 507:172–175

    Article  PubMed  Google Scholar 

  • Newhouse PA, Sunderland T, Tariot PN, Blumhardt CL, Weingartner H, Mellow A, Murphy DL (1988) Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology 95:171–175

    Google Scholar 

  • Nicholson CD (1990) Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology 101:147–159

    Google Scholar 

  • Nyback H, Nyman H, Nordgren I, Lindstrom B (1988) Preliminary experiences and results with THA for the amelioration of symptoms of Alzheimer's disease. In: Giacobini E, Becker R (eds) Current research in Alzheimer's therapy. Taylor and Francis, New York, pp 231–236

    Google Scholar 

  • Okazaki Y, Natori K, Irie T, Katsube J (1990) Effect of a novel CNS-selective cholinesterase inhibitor, SM-10888, on habituation and passive avoidance responses in mice. Jpn J Pharmacol 53:211–220

    PubMed  Google Scholar 

  • Palmer AM, Francis PT, Benton JS, Sims NR, Mann DMA, Neary D, Snowdon JS, Bowen DM (1987a) Presynaptic serotonergic dysfunction in patients with Alzheimer's disease. J Neurochem 48:8–15

    PubMed  Google Scholar 

  • Palmer AM, Francis PT, Bowen DM, Benton JS, Neary D, Mann DMA, Snowdon JS (1987b) Catecholaminergic neurons assessed ante-mortem in Alzheimer's disease. Brain Res 414:365–375

    Article  PubMed  Google Scholar 

  • Parsons DS, Peagler A, Barlow TS, Harrell LE (1987) Failure of chronic physostigmine to ameliorate working memory deficits after medial septal lesions. Exp Neurol 96:456–461

    Article  PubMed  Google Scholar 

  • Perry EK (1988) The cholinergic hypothesis-ten years on. Br Med Bull 42:63–69

    Google Scholar 

  • Piercey MF, Vogelsang GD, Franklin SR, Tang AH (1987) Reversal of scopolamine-induced amnesia and alterations in energy metabolism by the nootropic piracetam: implications regarding identification of brain structures involved in consolidation of memory traces. Brain Res 424:1–9

    Article  PubMed  Google Scholar 

  • Pontecorvo MJ, Evans HL (1985) Effects of aniracetam on delayed matching-to-sample performance of monkeys and pigeons. Pharmacol Biochem Behav 22:745–752

    Google Scholar 

  • Porsolt RD (1989) The silent epidemic: the search for treatment of age-related memory impairment. TIPS 10:3–6

    PubMed  Google Scholar 

  • Poschel BPH (1988) New pharmacological perspectives on nootropic drugs. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of psychopharmacology. Psychopharmacology of the aging nervous system, vol 20. Plenum Press, New York, pp 437–469

    Google Scholar 

  • Procter AW, Lowe SL, Palmer AM, Francis PT, Esiri MM, Stratmann GC, Naijlerahim A, Patel AJ, Hunt A, Bowen DM (1988) Topographical distribution of neurochemical changes in Alzheimer's disease. J Neurol Sci 84:125–140

    Article  PubMed  Google Scholar 

  • Quartermain D, Altman HJ (1982) Facilitation of retrieval byd-amphetamine following anisomycin-induced amnesia. Physiol Psychol 10:283–292

    Google Scholar 

  • Randt CT, Judge ME, Bonnet KA, Quartermain D (1982) Brain cyclic AMP and memory in mice. Pharmacol Biochem Behav 17:677–680

    Google Scholar 

  • Ridely RM, Baker HF, Drewett B, Johnson JA (1985) Effects of ibotenic acid lesions of the basal forebrain on serial reversal learning in marmosets. Psychopharmacology 86:438–443

    Google Scholar 

  • Ridely RM, Murray TK, Johnson JA, Baker HF (1986) Learning impairment following lesion of the basal nucleus of Meynert in the marmoset: modification cholinergic drugs. Brain Res 376:108–116

    Article  PubMed  Google Scholar 

  • Ridely RM, Baker HF, Drewett B (1987) Effects of arecoline and pilocarpine on learning ability with marmosets pretreated with hemicholinium-3. Psychopharmacology 91:512–514

    Google Scholar 

  • Ridely RM, Samson NA Baker HF, Johnson JA (1988) Visuospatial learning impairment following lesion of the cholinergic projection to the hippocampus. Brain Res 456:71–87

    Article  PubMed  Google Scholar 

  • Riekkinen P, Sirvio J, Riekkinen P (1990) The effects of THA on medial septal lesion induced memory deficits. Pharmacol Biochem Behav 36:237–241

    Google Scholar 

  • Robbins TW (1988) Arresting memory decline. Nature 336:207–208

    Article  PubMed  Google Scholar 

  • Robinson DS, Kurtz NM (1986) A scientific and pharmaceutical industry perspective. In: Crook T, Bartus R, Ferris S, Gershon S (eds) Treatment development strategies of Alzheimer's disease. Mark Powley, Madison, pp 655–670

    Google Scholar 

  • Rogers DC, Ballard TM, Hunter AJ, Hill RG (1990) Comparison of the effects of scopolamine and tacrine in the Morris water maze and delayed non-matching to sample task. Psychopharmacology 101 [suppl]:186

    Google Scholar 

  • Rupniak NMJ, Steventon MJ, Field MJ, Jennings CA, Iversen SD (1989) Comparison of the effects of four cholinomimetics agents on cognition in primates following disruption by scopolamine or by lists of objects. Psychopharmacology 99:189–195

    Google Scholar 

  • Rush DK (1986) Reversal of scopolamine-induced amnesia of passive avoidance by pre- and post-training naloxone. Psychopharmacology 89:296–300

    Google Scholar 

  • Russell RW (1964) Extrapolation from animals to man. In: Steinberg H (ed) Animal behavior and drug action. Churchill, London, pp 410–418

    Google Scholar 

  • Sahakian BJ, Jones G, Levy R, Gray J, Warburton D (1989) The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry 154:797–800

    PubMed  Google Scholar 

  • Sahgal A (1984) A critique of the vasopressin-memory hypothesis. Psychopharmacology 83:215–228

    Google Scholar 

  • Sansone M, Castellano C, Battaglia M, Ammassari-Teule M (1990) Oxiracetam prevents mecamylamide-induced impairment of active, but not passive, avoidance learning in mice. Pharmacol Biochem Behav 36:389–392

    Google Scholar 

  • Santucci AC, Kanof PD, Haroutunian V (1989) Effect of physostigmine on memory consolidation and retrieval processes in intact and nucleus basalis-lesioned rats. Psychopharmacology 99:70–74

    Google Scholar 

  • Sara SJ (1980) Memory retrieval deficits: alleviation by etiracetam, a nootropic drug. Psychopharmacology 68:235–241

    Google Scholar 

  • Sarter M, Steckler T (1989) Spontaneous exploration of a 6-arm radial tunnel maze by basal forebrain lesioned rats: effects of the benzodiazepine receptor antagonist β-carboline ZK 93 426. Psychopharmacology 98:193–202

    Google Scholar 

  • Sarter M, Stephens DN (1988) β-carbolines as tools in memory research: animal data and speculations. In: Hindmarch I, Ott H (eds) Benzodiazepine receptor ligands, memory and information processing. Springer, Berlin Heidelberg New York, pp 230–245

    Google Scholar 

  • Sarter M, Stephens DN (1989) Disinhibitory properties of β-carboline antagonists of benzodiazepine receptors: a possible therapeutic approach for senile dementia? Biochem Trans 17:81–83

    Google Scholar 

  • Sarter M, Bodewitz G, Stephens DN (1988) Attenuation of the scopolamine-induced impairment in spontaneous alternation behavior by antagonist but not inverse agonist and agonist β-carbolines. Psychopharmacology 94:491–495

    Google Scholar 

  • Sarter M, Bruno JP, Dudchenko P (1990) Activating the damaged basal forebrain cholinergic system: tonic stimulation versus signal amplification. Psychopharmacology 101:1–17

    Google Scholar 

  • Schindler U, Rush DK, Fielding S (1984) Nootropic drugs: Animal models for studying effects on cognition. Drug Dev Res 4:567–576

    Article  Google Scholar 

  • Shutske GM, Pierrat FA, Cornfeldt ML, Szewczak MR, Huger FP, Bores GM, Haroutunian V, Davis KL (1988) (+/-)-9-amino-1,2,3,4-tetrahydroacridin-1-ol. A potential Alzheimer's disease therapeutic of low toxicity. J Med Chem 31:1278–1279

    Article  PubMed  Google Scholar 

  • Spanis CW, Squire LR (1978) Elevation of brain tyrosine by hibitors of protein synthesis is not responsible for their amnesic effect. Brain Res 139:384–388

    Article  PubMed  Google Scholar 

  • Spear NE, Miller JS, Jagielo JA (1990) Animal memory and learning. Annu Rev Psychol 41:169–211

    Article  PubMed  Google Scholar 

  • Spignoli G, Pepeu G (1987) Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine. Pharmacol Biochem Behav 27:491–495

    Google Scholar 

  • Squire LR, Slater PC, Miller PL (1975) Retrograde amnesia: temporal gradient in very long-term memory following electroconvulsive therapy. Science 187:77–79

    PubMed  Google Scholar 

  • Stephens DN, Sarter M (1988) Bidirectional nature of benzodiazepine receptor ligands extends to effects in vigilance. In: Hindmarch I, Ott H (eds) Benzodiazepine receptor ligands, memory and information processing. Springer, Berlin Heidelberg New York, pp 205–217

    Google Scholar 

  • Stone WS, Croul CE, Gold PE (1988) Attenuation of scopolamine-induced amnesia in mice. Psychopharmacology 96:417–420

    Google Scholar 

  • Strong R, Hicks P, Hsu L, Bartus RT, Enna SJ (1980) Age-related alterations in the rodent brain cholinergic system and behavior. Neurobiol Aging 1:59–63

    Article  PubMed  Google Scholar 

  • Summers WK, Viesselamn JO, Marsh GM, Candelora K (1981) Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients. Biol Psychiatry 16:145–153

    PubMed  Google Scholar 

  • Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A (1986) Oral tetrahydroaminoacridine in long term treatment of senile dementia, Alzheimer type. N Engl J Med 315:1241–1245

    PubMed  Google Scholar 

  • Sweeney JE, Höhman CF, Moran TH, Coyle JT (1988) A long acting cholinestrase inhibitor reverses spatial memory deficits in mice. Pharmacol Biochem Behav 31:141–147

    Article  PubMed  Google Scholar 

  • Sweeney JE, Bachman ES, Coyle JT (1990) Effects of different doses of galanthamine, a long acting acetylcholinesterase inhibitor, on memory in mice. Psychopharmacology 102:191–200

    Google Scholar 

  • Takashima A, Itoh S (1988) Effect of V-9-M, a peptide fragment derived from procholecystokinin, on memory processes in the rat. Can J Physiol Pharmacol 67:228–231

    Google Scholar 

  • Tariot PN, Cohen RM, Welkowitz JA, Sunderland T, Newhouse PA, Murphy DL, Weingartner H (1988) Multiple-dose arecoline infusions in Alzheimer's disease. Arch Gen Psychiatry 45:901–905

    PubMed  Google Scholar 

  • Thal LJ, Dokla CPJ, Armstrong DM (1988) Nucleus basalis magnocellularis lesions: lack of biochemical and immunocytochemical recovery and affect of cholinesterase inhibitors on passive avoidance. Behav Neurosci 102:852–860

    Article  PubMed  Google Scholar 

  • Thompson TL, Filley CM, Mitchell WD, Culig KM, LoVerde M, Byny RL (1990) Lack of hydergine in patients with Alzheimer's disease. N Engl J Med 323:445–458

    PubMed  Google Scholar 

  • Tilson HA, McLamb RL, Shaw S, Rogers BC, Pediaditakis P, Cook L (1988) Radial-arm maze deficits produced by colchicine administered into the area of the nucleus basalis are ameliorated by cholinergic agents. Brain Res 438:83–94

    Article  PubMed  Google Scholar 

  • Tobe A, Egawa M, Nagai R (1983) Effect of 4-(o-benzylphenoxy)-N-methylbutylamine hydrochloride (MCI-2016) on the scopolamine-induced deficit of spontaneous alternation behavior in rats. Jpn J Pharmacol 33:775–784

    PubMed  Google Scholar 

  • Ueki A, Miyoshi K (1989) Effects of cholinergic drugs on learning impairment in ventral globus pallidus lesioned rats. J Neurol Sci 90:1–21

    Article  PubMed  Google Scholar 

  • Warburton DM, Wesnes K (1984) Drugs as research tools in psychology: cholinergic drugs and information processing. Neuropsychobiology 11:121–132

    PubMed  Google Scholar 

  • Wettstein A, Spiegel R (1984) Clinical trials with the cholinergic drug RS 86 in Alzheimer disease (AD) and senile dementia of the Alzheimer type (SDAT). Psychopharmacology 84:572–573

    Google Scholar 

  • Willner P (1984) The validity of animal models of depression. Psychopharmacology 83:1–16

    Google Scholar 

  • Willner P (1986) Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case. Progr Neuropsychopharmacol Biol Psychiatry 10:677–690

    Article  Google Scholar 

  • Wolters ECh, Riekkinen P, Lowenthal A, Van der Plaats JJ, Zwart JMT, Sennef C (1990) DGAVP (Org 5667) in early Alzheimer's disease patients: an international double-blind, placebo-controlled, multicenter trial. Neurology 40:1099–1101

    PubMed  Google Scholar 

  • Yamamoto M, Shimizu M (1988) Effects of a new TRH analogue, YM-14673 on a passive avoidance test as a possible criterion of improvement in cognitive disturbance in rodents. Arch Pharmacol 338:262–267

    Article  Google Scholar 

  • Yamazaki N, Kato K, Kurihara E, Nagaoka A (1991) Cholinergic drugs reverse AF64A-induced impairment of passive avoidance learning in rats. Psychopharmacology 103:215–222

    Google Scholar 

  • Zerbib R, Laborit H (1990) Chronic stress and memory: implication of the central cholinergic system. Pharmacol Biochem Behav 36:897–900

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychology, The Ohio State University, 27 Townshend Hall, 43210, Columbus, OH, USA

    Martin Sarter, Jim Hagan & Paul Dudchenko

Authors
  1. Martin Sarter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jim Hagan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul Dudchenko
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sarter, M., Hagan, J. & Dudchenko, P. Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I. Psychopharmacology 107, 144–159 (1992). https://doi.org/10.1007/BF02245132

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02245132

Key words

Search

Navigation